Matts Kågedal
Matts Kågedal
Bestätigte E-Mail-Adresse bei gene.com
Titel
Zitiert von
Zitiert von
Jahr
Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity
M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ...
Pharmaceutical research 14 (2), 176-180, 1997
561997
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33 (1), 75-91, 2006
502006
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model
PH Zingmark, M Kågedal, MO Karlsson
Journal of pharmacokinetics and pharmacodynamics 32 (2), 261-281, 2005
452005
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region
M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ...
Neuroimage 82, 160-169, 2013
342013
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde
International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013
252013
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ...
Neuroimage 61 (4), 849-856, 2012
242012
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C …
K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ...
Psychopharmacology 213 (2-3), 533-545, 2011
242011
Distribution of zolmitriptan into the CNS in healthy volunteers
A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ...
Drugs in R & D 6 (3), 139-147, 2005
222005
PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ...
European Neuropsychopharmacology 18, S270-S270, 2008
202008
True nasopharangeal absorption of zolmitriptan following administration of zolmitriptan nasal spray
PH Zingmark, R Yates, C Hedlund, M Kagedal
European Journal of Neurology Supplement 10, 2003
152003
Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers
J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz
European Journal of Pain 17 (10), 1465-1471, 2013
112013
Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066, and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorders. Abstract PT444
L Ståhle, R Karlsten, B Jonzon, B Eriksson, M Kågedal, A Dominicus
Proceedings of the 14th World Congress on Pain, Milan, Italy, 2012
102012
Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens
D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ...
CPT: pharmacometrics & systems pharmacology 6 (6), 401-408, 2017
92017
Early phase drug development for treatment of chronic pain—Options for clinical trial and program design
J Kalliomäki, F Miller, M Kågedal, R Karlsten
Contemporary clinical trials 33 (4), 689-699, 2012
82012
Autoradiographic mapping of 5-HT1B/1D binding sites in the rhesus monkey brain using [carbonyl-11C] zolmitriptan
Ö Lindhe, P Almqvist, M Kågedal, SÅ Gustafsson, M Bergström, D Nilsson, ...
International journal of molecular imaging 2011, 2011
72011
A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime
M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ...
Journal of clinical pharmacology 47 (8), 1043-1049, 2007
62007
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ...
The Journal of Clinical Pharmacology 59 (5), 702-716, 2019
52019
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li
Cancer Chemotherapy and Pharmacology 80 (6), 1147-1159, 2017
52017
Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates
M Kågedal, L Gibiansky, J Xu, X Wang, D Samineni, SC Chen, D Lu, ...
Journal of Pharmacokinetics and Pharmacodynamics 44 (6), 537-548, 2017
52017
Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
J Maringwa, M Kågedal, UW Hamrén, P Martin, E Cox, B Hamrén
The Journal of Clinical Pharmacology 55 (3), 328-335, 2015
52015
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20